StreetAlpha
13F holdings · Q3 2026

Stonepine Capital Management

Bend, OR · files as Stonepine Capital Management, LLC
Know the moment Stonepine Capital Management filesYou follow Stonepine Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1440771

Stonepine Capital Management reported 66 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are VSTM (20.4%), CAMP (9.4%) and EOLS (6.5%). Compared with Q2 2026, the fund opened new positions in BSX, PYXS and SRZN, added to CAMP, KZIA and RARE, trimmed VSTM, EOLS and ADMA and sold out of RADX, TELA and CRIS.

Latest filing: what Stonepine Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
18 new20 added26 trimmed24 sold outBought about $25.3M · sold about $245M
New 18
See all 18 →
Added 20
See all 20 →
Trimmed 26
See all 26 →
Sold out 24
See all 24 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$120M−64.9% vs last quarter · $159M including options
Stocks held6618 new · 24 sold out
Top 5 weight47.8%fairly concentrated
Turnover226%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
VSTM
Verastem Inc
$24.5M20.4%3M−307K (−9%)8 of 8
2
CAMP
CAMP4 Therapeutics Corp
$11.3M9.4%2.8M+1.4M (+101%)4 of 8
3
EOLS
Evolus Inc
$7.8M6.5%972K−619K (−39%)8 of 8
4
ADMA
Adma Biologics Inc
$7M5.9%700K−40K (−5%)8 of 8
5
NKTR
Nektar Therapeutics
$6.7M5.6%110K−11K (−9%)6 of 8
6
ELOX
Eloxx Pharmaceuticals Inc
$5.8M4.9%382K−15K (−4%)2 of 8
7
MSLE
Satellos Bioscience Inc
$3.9M3.2%455K−37K (−7%)3 of 8
8
KZIA
Kazia Therapeutics Ltd
$3.6M3.0%377K+32K (+9%)4 of 8
9
INDV
Indivior PLC
$3.6M3.0%100KNo change2 of 8
10
RARE
Ultragenyx Pharmaceutical in
$3.2M2.6%210K+185K (+740%)3 of 8
🔒 56 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
RADX
Radiopharm Theranostics Ltd
$211M51M
TELA
Tela Bio Inc
$2M2.7M
CRIS
Curis Inc
$1.7M3.3M
SPRB
Spruce Biosciences Inc
$1.6M29K
SLGL
Sol Gel Technologies
$1.1M14K

🔒 Free account: see all 24.

Options

valued at the underlying shares
StockTypeValueSharesChange
INSM
Insmed Inc
Call$5.6M40K0
ADMA
Adma Biologics Inc
Call$5.2M400K−250,000
EOLS
Evolus Inc
Call$5M500K+80,000
ZLAB
Zai Lab Ltd
Call$4.5M150K+150,000
ESTA
Establishment Labs Hldgs Inc
Call$4.3M50K+50,000

🔒 Free account: see all 12.

Reported value

last 8 quarters
$124MQ4 '24
$119MQ1 '25
$102MQ2 '25
$123MQ3 '25
$393MQ4 '25
$332MQ1 '26
$342MQ2 '26
$120MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Stonepine Capital Management 13F FAQ

What does Stonepine Capital Management own?

Stonepine Capital Management reported 66 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are VSTM (20.4%), CAMP (9.4%) and EOLS (6.5%). The table above lists every position in the filing (the top 10 without an account).

What did Stonepine Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 18 new positions, 20 added to, 26 trimmed and 24 sold out. New positions include BSX, PYXS and SRZN. It sold all of RADX, TELA and CRIS.

When will Stonepine Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Stonepine Capital Management's portfolio worth?

The Q3 2026 filing reports $120M in US stocks ($159M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.